SEC Comment Letter for LiveCare, Inc. (LVCE) (CIK 0001762400) — Jun 30, 2022
LiveCare, Inc. (LVCE) (CIK 0001762400)
Date: June 30, 2022 · CIK: 0001762400 · Accession: 0000000000-22-007031
AI Filing Summary & Sentiment
File numbers found in text: 024-11914
Letter
United States securities and exchange commission logo June 30, 2022 John Brannelly General Counsel LiveCare, Inc. 12465 South Fort Street Ste 240 Draper, UT 84020 Re:LiveCare, Inc. Offering Statement on Form 1-A Filed June 21, 2022 File No. 024-11914 Dear Mr. Brannelly: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Doris Stacey Gama at 202-551-3188 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John Brannelly, Esq.
Show Raw Text
United States securities and exchange commission logo
June 30, 2022
John Brannelly
General Counsel
LiveCare, Inc.
12465 South Fort Street Ste 240
Draper, UT 84020
Re:LiveCare, Inc.
Offering Statement on Form 1-A
Filed June 21, 2022
File No. 024-11914
Dear Mr. Brannelly:
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257
of Regulation A requires you to file periodic and current reports, including a Form 1-K which
will be due within 120 calendar days after the end of the fiscal year covered by the report.
Please contact Doris Stacey Gama at 202-551-3188 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: John Brannelly, Esq.